ENTRY       D11560            Mixture   Drug
NAME        Trastuzumab and hyaluronidase;
            Trastuzumab and hyaluronidase-oysk;
            Herceptin hylecta (TN)
PRODUCT     HERCEPTIN HYLECTA (Genentech)
COMPONENT   Trastuzumab [DR:D03257], Hyaluronidase (human recombinant) [DR:D06604]
CLASS       Antineoplastic
             DG01918  Tyrosine kinase inhibitor
              DG01917  Receptor tyrosine kinase inhibitor
               DG03158  HER2 inhibitor
REMARK      ATC code: L01FD01
            Product: D11560<US>
EFFICACY    Antineoplastic (adjuvant)
  DISEASE   Breast cancer (HER2 overexpressing or ER/PR negative) [DS:H00031]
  TYPE      Monoclonal antibody, combination
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
                L01FD HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
                 L01FD01 Trastuzumab
                  D11560  Trastuzumab and hyaluronidase &lt;US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Monoclonal Antibody/Antibody-Drug Conjugate
               Trastuzumab/ Hyaluronidase
                D11560  Trastuzumab and hyaluronidase
            Drug groups [BR:br08330]
             Antineoplastic
              DG01918  Tyrosine kinase inhibitor
               DG01917  Receptor tyrosine kinase inhibitor
                DG03158  HER2 inhibitor
                 D11560  Trastuzumab and hyaluronidase
            Drug classes [BR:br08332]
             Antineoplastic
              DG03158  HER2 inhibitor
               D11560  Trastuzumab and hyaluronidase
DBLINKS     PubChem: 384585536
///
